Stanford researchers have engineered hematopoietic stem cells to provide long-term secretion of chosen therapeutic antibodies, eliminating the need of repeated dosing for delivery.
Using their newly developed acetyl-click screening platform, researchers at Stanford have identified riboflavin analogs as small molecule inhibitors of Histone Acetyltransferase 1 (HAT1) with anti-cancer activity.